The Ledger GazetteUS Stem Cell (OTCMKTS:USRM) Issues Earnings ResultsThe Ledger GazetteU.S. Stem Cell (OTCMKTS:USRM) posted its earnings results on Monday, April 16th. The company reported $0.05 earnings per share for the quarter, Bloomberg Earnings re… Continue reading
FiercePharmaCTG Catapult opens its new unique cell and gene therapy plant in the UKFiercePharmaThe launch of this important facility pushes the agenda forward and accelerates the timeframe for bringing these living medicines to patients.” Initial partn… Continue reading
FiercePharmaCTG Catapult opens its new unique cell and gene therapy plant in the UKFiercePharmaThe launch of this important facility pushes the agenda forward and accelerates the timeframe for bringing these living medicines to patients.” Initial partn… Continue reading
PR Newswire (press release)Market Demand for Stem Cell Treatments Driving Steady Increase in USRM SalesPR Newswire (press release)"Our increase in patients is providing us with an opportunity to serve the needs of more and more patients who had gi… Continue reading
PR Newswire (press release)Market Demand for Stem Cell Treatments Driving Steady Increase in USRM SalesPR Newswire (press release)"Our increase in patients is providing us with an opportunity to serve the needs of more and more patients who had gi… Continue reading
Immuno-Oncology NewsCAR T-cell Therapy at Higher Dose Might Treat Advanced Neuroblastoma, Early Trial Results SuggestImmuno-Oncology NewsIn this first clinical study in patients (NCT02761915), researchers are investigating the safety and the potential … Continue reading
Genetic Literacy Project |
Synthetic biology and viewing life not as ‘a mystery but as a machine’
Genetic Literacy Project Imagine a future where synthetic jellyfish roam waterways looking for toxins to destroy, where eco-friendly plastics and fuels are harvested from vats of yeast, where viruses are programmed to be cancer killers, and electronic gadgets repair themselves … |
Genetic Literacy Project |
Chinese biopharma firms ‘well ahead’ in race to use CRISPR in humans
Genetic Literacy Project Contrary to what you might believe, biopharma companies in the US are not the leaders in clinical trials using gene editing tech. While a slate of US/European pioneers have been lining up their first human trials, investigators in China are already … |